kannalife.com is a domain
that was created on 2010-05-09,making it 14 years ago.
It has several subdomains, such as investors.kannalife.com , among others.
Description:KannaLife Sciences, Inc. (a subsidiary of Neuropathix, Inc.) is a biopharmaceutical company focused on the research and development of a pipeline of next generation breakthrough therapeutics...
Keywords:GPCR, GPCRs, G Coupled protein receptors, GPR55, NLRP3, inflammasome, NCX-1, sodium-calcium...
Discover kannalife.com website stats, rating, details and status online.Use our online tools to find owner and admin contact info. Find out where is server located.Read and write reviews or vote to improve it ranking. Check alliedvsaxis duplicates with related css, domain relations, most used words, social networks references. Go to regular site
HomePage size: 74.38 KB |
Page Load Time: 0.347625 Seconds |
Website IP Address: 104.197.22.116 |
Covid-19 and the Social Sciences - Covid-19 and the Social Sciences - Social Science Research Counci |
Land Resources and Environmental Sciences - Land Resources and Environmental Sciences | Montana Stat |
Jobs at Integra Life Sciences | Careers at Integra Life Sciences | | Apply Online |
Faculty of Health Sciences - Faculty of Health Sciences |
College of Sciences | College of Sciences | Georgia Institute of Technology | Atlanta, GA |
Welcome to Augustus C. Long Health Sciences Library | Augustus C. Long Health Sciences Library |
Home | Cognitive Sciences | UCI Social Sciences |
The College of Arts & Sciences has become two different colleges! | College of Arts & Sciences | Eas |
College of Arts and Sciences - College of Arts and Sciences | University of South Carolina |
Psychological and Brain Sciences | College of Liberal Arts and Sciences | The University of Iowa |
Welcome to Strauss Health Sciences Library | Strauss Health Sciences Library |
Home | College of Liberal Arts & Sciences | College of Liberal Arts & Sciences |
Neuropathix, Inc. – A Phyto-Medical Company | Developing Pharmaceuticals to Protect the Brain |
Homepage - Kannalife Sciences, Inc. – A Neuropathix Company https://www.kannalife.com/ |
Developing Pharmaceuticals to Protect the Brain: Neuropathix ... http://investors.kannalife.com/ |
Financial Conflicts of Interest in Research Policy https://www.kannalife.com/coipolicy/ |
Science - Kannalife Sciences, Inc. – A Neuropathix Company https://www.kannalife.com/science/ |
Leadership - Kannalife Sciences, Inc. – A Neuropathix ... https://www.kannalife.com/leadership/ |
About - Kannalife Sciences, Inc. – A Neuropathix Company https://www.kannalife.com/about/ |
Contact - Kannalife Sciences, Inc. – A Neuropathix Company https://www.kannalife.com/contact/ |
Investors - Kannalife Sciences, Inc. – A Neuropathix ... https://www.kannalife.com/investors/ |
Thoma Kikis - Kannalife Sciences, Inc. – A Neuropathix ... https://www.kannalife.com/thoma-kikis/ |
Dean Petkanas - Kannalife Sciences, Inc. – A Neuropathix ... https://www.kannalife.com/dean-petkanas/ |
A kannalife.com. 600 IN A 104.197.22.116 |
MX kannalife.com. 3600 IN MX 20 alt2.aspmx.l.google.com. |
NS kannalife.com. 3600 IN NS ns07.domaincontrol.com. |
TXT kannalife.com. 3600 IN TXT v=spf1 +a +mx +ip4:69.89.27.245 ?all |
SOA kannalife.com. 3600 IN SOA ns07.domaincontrol.com. dns.jomax.net. 2020072402 28800 7200 604800 600 |
Server: nginx |
Date: Tue, 14 May 2024 10:47:18 GMT |
Content-Type: text/html; charset=UTF-8 |
Content-Length: 71765 |
Connection: keep-alive |
Keep-Alive: timeout=20 |
Vary: Accept-Encoding, Accept-Encoding, Accept-Encoding, Accept-Encoding,Cookie |
Link: https://www.kannalife.com/wp-json/; rel="https://api.w.org/", https://www.kannalife.com/wp-json/wp/v2/pages/529; rel="alternate"; type="application/json", https://www.kannalife.com/; rel=shortlink |
X-Powered-By: WP Engine |
X-Cacheable: SHORT |
Cache-Control: max-age=600, must-revalidate |
Accept-Ranges: bytes |
X-Cache: HIT: 1 |
X-Cache-Group: normal |
charset="utf-8"/ |
content="width=device-width" name="viewport"/ |
content="index, follow, max-image-preview:large, max-snippet:-1, max-video-preview:-1" name="robots" |
content="KannaLife Sciences, Inc. (a subsidiary of Neuropathix, Inc.) is a biopharmaceutical company focused on the research and development of a pipeline of next generation breakthrough therapeutics targeting inflammation to treat patients with significant unmet medical needs. Over the past ten years, Neuropathix has discovered, developed, and patented a global intellectual property estate, led by its lead clinical target, KLS-13019, as novel, new therapeutic agents designed to prevent and reverse neuropathic pain, reduce oxidative stress, and act as anti-inflammatory neuroprotectants. The Company's family of patented monotherapeutic molecules focuses on treating oxidative stress-related diseases, chronic pain management, and neurodegenerative disorders. Kannalife conducts its research and development efforts at the Pennsylvania Biotechnology Center of Bucks County in Doylestown, PA." name="description" |
content="GPCR, GPCRs, G Coupled protein receptors, GPR55, NLRP3, inflammasome, NCX-1, sodium-calcium exchanger, mitochondria function, mitochondria, mitochondria dysfunction, breakthrough therapeutics, targeting inflammation, socially responsible, non-opioid, opioid alternatives, KLS-13019, NPTX-204, cannabinoids, synthetic cannabinoids, cannabinoid-inspired, cannabinoid derivatives, CIPN, peripheral neuropathy, neuropathic pain, unmet medical needs, kannalife, pharmaceutical, biotechnology, botanical, medicine, cannabis, cannabinoids, endocannabinoids, antioxidants, neuroprotectants, phytocannabinoids, phytopharmaceutical, terpene, terpenes, cannatol, kannalife, cannalife, kannabis, government patent on cannabinoids, cannabinoid patent, cannabinol, CBN, cannabidiol, CBD, cannabigerol, CBG, cannabichromene, CBC, tetrahydrocannabinol, tetrahydrocannabivarin, THCV, cannabicyclol, CBL, cannabivarin, CBV, cannabicitran, CBT, cannabidivarin, CBDV, cannabichromevarin, CBCV, cannabigerovarin, CBGV, cannabigerol monomethyl ether, CBGM, Arachidonoylethanolamine, AEA, anandamide, 2-arachidonoyl glycerol, 2-AG, 2-arachidonyl glyceryl ether, noladin ether, N-arachidonoyl-dopamine, NADA, virodhamine, OAE, lysophosphatidylinositol, LPI, novel therapeutics, neuropathix" name="keywords"/ |
content="web" name="distribution"/ |
content="en_US" property="og:locale"/ |
content="website" property="og:type"/ |
content="Homepage - Kannalife Sciences, Inc. – A Neuropathix Company" property="og:title"/ |
content="Kannalife Sciences, a subsidiary of Neuropathix, Inc., is a biopharmaceutical company focused on the research and development of a pipeline of next generation breakthough therapeutics targeting inflammation to treat patients with significant unmet medical needs." property="og:description"/ |
content="https://www.kannalife.com/" property="og:url"/ |
content="Kannalife Sciences, Inc. – A Neuropathix Company" property="og:site_name"/ |
content="2024-04-11T01:49:02+00:00" property="article:modified_time"/ |
content="Powered by Slider Revolution 6.1.1 - responsive, Mobile-Friendly Slider Plugin for WordPress with comfortable drag and drop interface." name="generator"/ |
content="https://www.kannalife.com/wp-content/themes/kanna_v2/screenshot.png" property="og:image"/ |
Ip Country: United States |
City Name: Council Bluffs |
Latitude: 41.2591 |
Longitude: -95.8517 |
Leadership Science Contact Stay Ahead | |Search for: Subsidiary Kannalife Sciences, Inc. Awarded Phase 2 Study Grant from National Institute of Neurological Disorders and Stroke (NINDS) as part of the NIH HEAL Initiative Learn More Kannalife awarded $2.97M grant from NIH 1/4 We’re a Biopharmaceutical Company Engineering Breakthough Therapeutics Targeted for the Treatment of Inflammation, Neurodegeneration, Oxidative Stress and Neuropathic Pain Related Diseases. Visit Website Kannalife Sciences is Targeting Inflammation 2/4 We’re Deploying the Most Creative and Innovative Scientific Minds to Discover and Bring to Market Novel Cannabinoid Therapeutics for Patients with Serious Unmet Medical Needs. Learn More The Science of Kannalife 3/4 CEO Dean Petkanas and Dr. Brenneman talk to NBC’s Dateline about the science of CBD-like therapeutic compounds and their broad potential, including the treatment of pain without opioids. Watch Video Kannalife on Dateline NBC 4/4 Kannalife Sciences, a subsidiary of Neuropathix, Inc., is a biopharmaceutical company focused on the research and development of a pipeline of next generation breakthough therapeutics targeting inflammation to treat patients with significant unmet medical needs. Kannalife, Inc. Appoints Dr. Tage Honoré as Chairman of the Company’s Board of Advisors Kannalife, Inc. Bolsters IP Portfolio with Multiple Patents Issued in 12 Key European Territories Kannalife, Inc. Appoints Terrence O. Tormey to the Company’s Board of Advisors Kannalife, Inc. Announces Results from Comparative UVB-Radiation Study on Atopidine™ Versus CBD Kannalife, Inc. Receives Notice of Allowance from USPTO for Trademark of Atopidine™ Kannalife Bolsters its Global Intellectual Property Portfolio with New Chinese-Issued Patent Kannalife, Inc. Announces Completion of NIH-NIDA Phase 1 Grant and Results from Lewis Katz School of Medicine at Temple University for the Potential Use of KLS-13019 in the Treatment of CIPN Kannalife, Inc. CEO Recaps 2019 Advances and Potential Ahead CBD: Perils, Promise and Development for Neuropathic Pain About Science For almost a decade, Kannalife has been a leader in the research, development and discovery of novel Cannabinoid therapeutic agents for targeted drug candidates to treat Chemotherapy Induced Peripheral Neuropathy (CIPN), Hepatic Encephalopathy (HE), Mild Traumatic Brain Injury (mTBI) and chronic pain management. Kannalife has advanced the development of a proprietary product platform of innovative CBD-like molecules for patients with these diseases and other significant medical needs. We have taken a science based, data-driven, validated approach to the discovery and development of novel and promising therapeutic molecules that are similar to CBD. We are the only company in the cannabinoid therapeutics arena to have licensed the U.S. Government Patent 6,630,507 – Cannabinoids as Antioxidants and Neuroprotectants”. Our pre-clinical research on cannabidiol (CBD) and understanding of certain mechanism of action, its potential and its limitations, has resulted in our own target drug candidate discovery aimed at improving CBD’s pharmacokinetic and pharmacodynamic (PK/PD”) aptitude. In the discovery of KLS-13019 and other patented CBD-like New Chemical Entities (NCE’s), we have made significant improvements in the chemistry efficacy and safety of CBD-like molecules that are up to 200X more potent, 10X more bioavailable, 5X safer and 1000 times more effective than CBD. Get the Latest in Kannalife News Subscribe * indicates required Email Address * Home About Leadership Science Contact Copyright © 2024 Kannalife Sciences, Inc. All rights reserved. COI Policy. Home About Leadership Science...
Domain Name: KANNALIFE.COM Registry Domain ID: 1596486413_DOMAIN_COM-VRSN Registrar WHOIS Server: whois.godaddy.com Registrar URL: http://www.godaddy.com Updated Date: 2023-05-09T03:18:57Z Creation Date: 2010-05-09T18:51:51Z Registry Expiry Date: 2028-05-09T18:51:51Z Registrar: GoDaddy.com, LLC Registrar IANA ID: 146 Registrar Abuse Contact Email: abuse@godaddy.com Registrar Abuse Contact Phone: 480-624-2505 Domain Status: clientDeleteProhibited https://icann.org/epp#clientDeleteProhibited Domain Status: clientRenewProhibited https://icann.org/epp#clientRenewProhibited Domain Status: clientTransferProhibited https://icann.org/epp#clientTransferProhibited Domain Status: clientUpdateProhibited https://icann.org/epp#clientUpdateProhibited Name Server: NS07.DOMAINCONTROL.COM Name Server: NS08.DOMAINCONTROL.COM DNSSEC: unsigned >>> Last update of whois database: 2024-05-17T23:35:39Z <<<